Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Waldenstrom Macroglobulinemia
Elevated Risk for Cause-Specific Mortality in Waldenström Macroglobulinemia
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Deepened Responses in Waldenström Macroglobulinemia After Rituximab
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
Subtype of CXCR4 Mutation Correlated With Inferior Response to Ibrutinib in Waldenström Macroglobulinemia
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Next post in Lymphoma
